Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease

INTRODUCTION: Performance of the amyloid tracer [(18)F]flutemetamol was evaluated against three pathology standard of truth (SoT) measures including neuritic plaques (CERAD “original” and “modified” and the amyloid component of the 2012 NIA-AA guidelines). METHODS: After [(18)F]flutemetamol imaging,...

Descripción completa

Detalles Bibliográficos
Autores principales: Salloway, Stephen, Gamez, Jose E., Singh, Upinder, Sadowsky, Carl H., Villena, Teresa, Sabbagh, Marwan N., Beach, Thomas G., Duara, Ranjan, Fleisher, Adam S., Frey, Kirk A., Walker, Zuzana, Hunjan, Arvinder, Escovar, Yavir M., Agronin, Marc E., Ross, Joel, Bozoki, Andrea, Akinola, Mary, Shi, Jiong, Vandenberghe, Rik, Ikonomovic, Milos D., Sherwin, Paul F., Farrar, Gill, Smith, Adrian P.L., Buckley, Christopher J., Thal, Dietmar Rudolf, Zanette, Michelle, Curtis, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Neuroimaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536824/
https://www.ncbi.nlm.nih.gov/pubmed/28795133
http://dx.doi.org/10.1016/j.dadm.2017.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536824/
https://www.ncbi.nlm.nih.gov/pubmed/28795133
http://dx.doi.org/10.1016/j.dadm.2017.06.001

Ejemplares similares